Analytical Validation of qPCR-Based Multivariate Index Assays in a Clinical Laboratory: Practical Challenges and Limitations.

Background: Multivariate index assays (MIAs) to evaluate disease status and/or therapeutic efficacy are increasingly being used in clinical laboratories as laboratory-developed tests (LDTs). Before clinical use, diagnostic and analytical performance specifications of LDTs must be established. Several regulatory guidelines have been published that address specific components of validation procedures, but the interpretation for the analytical validation of MIAs is ambiguous and creates confusion when implementing a novel MIA in the clinical laboratory. Content: CLSI guidelines and published methods were evaluated to develop a validation strategy to establish analytical sensitivity, precision, specificity, and stability for qPCR-based MIAs. Limitations and challenges identified while evaluating guidelines and literature and implementing this strategy are discussed in this review, including sample sourcing and integrity, laboratory contamination, and sample throughput. Due to the diversity of qPCR-based MIAs, we discuss additional considerations for researchers intending to transfer MIAs to a clinical laboratory. Summary: A practical strategy to assess the analytical performance characteristics for validation of qPCR-based MIAs was developed and tested before diagnostic clinical use. Several important limitations, challenges, and considerations were identified during development of the analytical validation procedures that are not addressed in regulatory guidelines or published literature. The described strategy can provide insight for future developers of MIAs and clinical laboratories implementing MIAs as LDTs.

[1]  Xuefeng Yin,et al.  Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays. , 2013, Methods.

[2]  M. Gulley,et al.  Recommended principles and practices for validating clinical molecular pathology tests. , 2009, Archives of pathology & laboratory medicine.

[3]  D. Mavroudis,et al.  Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR , 2011, BMC Cancer.

[4]  Carole A. Foy,et al.  Considerations for accurate gene expression measurement by reverse transcription quantitative PCR when analysing clinical samples , 2014, Analytical and Bioanalytical Chemistry.

[5]  C. Denkert,et al.  Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test , 2012, BMC Cancer.

[6]  C. Sturgeon,et al.  Taking a new biomarker into routine use – A perspective from the routine clinical biochemistry laboratory , 2010, Proteomics. Clinical applications.

[7]  Richard Bourgon,et al.  High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing , 2014, Clinical Cancer Research.

[8]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[9]  Eileen M. Burd,et al.  Validation of Laboratory-Developed Molecular Assays for Infectious Diseases , 2010, Clinical Microbiology Reviews.

[10]  C. Schrader,et al.  PCR inhibitors – occurrence, properties and removal , 2012, Journal of applied microbiology.

[11]  Jean-Baptiste Veyrieras,et al.  A strategy to build and validate a prognostic biomarker model based on RT-qPCR gene expression and clinical covariates , 2015, BMC Bioinformatics.

[12]  A. Hartmann,et al.  Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens , 2016, BMC Cancer.

[13]  Iris Schrijver,et al.  Test verification and validation for molecular diagnostic assays. , 2012, Archives of pathology & laboratory medicine.

[14]  T. Davison,et al.  Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. , 2015, The Journal of molecular diagnostics : JMD.

[15]  A. Gutin,et al.  Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma. , 2015, Biomarkers in medicine.

[16]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[17]  A. Gutin,et al.  Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions. , 2015, Biomarkers in medicine.

[18]  J. Reid,et al.  Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer , 2015 .

[19]  Marc Salit,et al.  Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design , 2016, bioRxiv.

[20]  Rui Cheng,et al.  Classification of colon cancer based on the expression of randomly selected genes. , 2015, Genetics and molecular research : GMR.

[21]  Andrea C. Rinaldi,et al.  Teaming up for biomarker future , 2011, EMBO reports.

[22]  Mikael Kubista,et al.  How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments , 2015, Biomolecular detection and quantification.